Increased expression of FGF8 has also been reported in pancreatic ductal adenocarcinoma patients who have undergone neo-adjuvant therapy, suggesting that FGF8 is a prospective target for novel anticancer therapeutics [18]. Here, FGF8 is linked to pancreatic ductal adenocarcinoma.